Trump's Pharma Tariffs Threaten Industry Stability and Innovation
TL;DR
President Trump’s proposal to impose tariffs on pharmaceutical imports aims to address trade imbalances but risks disrupting the supply of essential medicines in the U.S., which heavily depends on China and India for raw materials. While bringing manufacturing back to the U.S. could enhance national security, the low margins and high costs make it challenging, and a comprehensive approach involving innovation, modernization, and large-scale initiatives is needed to reduce dependency and ensure drug supply stability.
Topics:businesspolitics#china-india-dependence#drug-supply-chain#national-security#pharmaceutical-tariffs#politics#us-manufacturing
- Trump’s Pharmaceutical Tariffs Are Not the Right Solution for a Big Problem Rolling Stone
- Trump’s tariff threat exposes China’s tight grip on the global pharmaceuticals industry CNN
- Industry leaders warn Trump's threatened pharma tariffs will backfire FirstWord Pharma
- Shoring Up the Healthcare Packaging Supply Chain is a Lot Like Flying a Plane Healthcare Packaging
- Rare disease, cell and gene therapy at risk from Trump tariffs, industry says PharmaLive
Want the full story? Read the original reporting
Read on Rolling Stone